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Abstract [‘ZSI]Cholecystokinin-S-S (CCK-8-S) bound to a single class of saturable binding sites on the human neuroblastoma cell line IMR-32 
(Kn = 4 f 1.5 nM, B,, = 10,500 ?r 3,500 sites/cell (n = 6)). These binding sites were of the CCK, type, as demonstrated by the differential inhibition 
of the binding of [‘2SI]CCK-8-S and CCK-S-S-induced ‘?a*+ efIlux by the specific CCK, antagonist SR 27897 and the specific CCK, antagonist 
PD 134,308. CCKJMV-180, an analogue of CCK-8-S which has been shown to activate 45Ca2’ e&x in rat cells in a manner similar to CCK-I-S, 
acted as a potent antagonist of CCK-l-S-induced 45Ca2+ efflux (IC, = 50 nM) and inhibited [‘zsT]CCK-8-S binding to IMR-32 cells (I&, = 1.7 nM). 
These results show that, unlike its CCK-like effect in various animal systems, CCK-JMC-180 acts as an antagonist of CCK, receptors in the human 
neuroblastoma cell line IMR-32. 
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1. Introduction 
The existence of two distinct types of cholecystokinin (CCK- 
8-S) receptors, CCK, and CCK, receptors, is now clearly es- 
tablished since the determination of their deduced amino acid 
sequence [ 1,2]. Whereas CCK, receptors are prominent in pan- 
creatic acinar cells and gallbladder smooth muscle cells, CCK, 
receptors are primarily localized on gastrointestinal smooth 
muscle cells and in the brain [3,4]. CCK, receptors have been 
studied essentially in rat and mouse pancreatic acini where 
cholecystokinin octapeptide (CCK-8-S) induces amylase re- 
lease [5]. The concentration-effect relationship of CCK-8-S in 
this tissue is somewhat peculiar, because release of amylase is 
stimulated at low concentrations of CCK-8-S, but decreases at 
higher concentrations of the peptide, although only one CCK, 
receptor seems to be present on these cells [5]. Interestingly, a 
peptide analogue of CCK-8-S, CCK-JMV-180, induces amy- 
lase release without a decrease at higher concentrations, and is 
able to inhibit the decrease produced by CCK-8-S [6]. Several 
explanations have been considered to explain these findings. 
Clearly, amylase release is Ca’+-dependent, because it is abol- 
ished by removal of extracellular Ca2’, and both CCK-8-S and 
CCK-JMV-180 induce an efflux of 45Ca2+ in pancreatic acini 
[7,8]. However, the intracellular mechanism inducing this Ca2+ 
release is not yet clearly established. Considering the fact that 
IP, production is not measurable at low concentrations of 
CCK-8-S and at any concentration of CCK-JMV-180 [7], and 
that inhibition of phospholipase C [9] or of intracellular IP3 
receptors [lo] inhibits the effects of CCK-8-S, but not those of 
CCK-JMV-180 on intracellular free Ca2’, it has been proposed 
that the second inhibitory phase of amylase release is due to the 
activation of phosphoinositide hydrolysis, whereas the first 
phase is due to an unknown second messenger able to induce 
Ca2+ oscillations in these cells [9,10]. This may correlate with 
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the existence of at least two [5] but perhaps three [l I], different 
states of the CCK, receptor in pancreatic acini, with a higher 
atiinity state mediating the activation and a lower affinity state 
the inhibition of amylase release [5]. This has led to the hypoth- 
esis that responses which are activated by CCK-JMV-180 are 
due to the higher affinity receptor state, whereas responses 
inhibited by CCK-JMV-180 are mediated by the lower atTinity 
receptor state [12,13]. However, recent studies show that in 
CHO cells expressing high levels of cloned rat CCK, receptors, 
CCK-JMV-180 is able to activate phosphoinositide hydrolysis 
[14], suggesting that in different cells CCK-8-S and CCK-JMV- 
180 will have contrasting effects depending on the level of, 
receptors and the second messenger systems present. Actually, 
whereas CCK-JMV-180 inhibits the CCK-&S-induced inhibi- 
tion of food intake in rats, it acts as an agonist of this response 
in mice [13]. 
It was therefore interesting to determine how the effects of 
CCK-8-S and CCK-JMV-180 compare on human receptors. 
We show here that in the human neuroblastoma cell line IMR- 
32 [15], CCK-JMV- 180 binds to CCK, receptors with an afEn- 
ity close to that of CCK-8-S and acts as an antagonist of CCK, 
receptor-induced 4sCa2+ etllux. 
2. Materials and methods 
2.1. Compoundr 
SR 27897 and PD 134308 were synthesized by San06 Recherche 
(Toulouse, France). lTyr(SO,H)*‘]Cholecystokinin fragment 26-33 
amide (CCK-8-S) and CCK-8-NS were from Sigma Chemical Co. 
(St. Louis. MO). CCK-JMV-180 was ourchased from Research Plus 
(Bayonne,‘NJ). “CaCl, (10-40 mCi/mmbl) and [r”IjCCK-8-S (2,000 Ci/ 
mmol) were from Amersham (Les Ulis, France). Tissue culture reagents 
were from Boehringer-Mannheim (Mannheim, Germany). 
2.2. Cell culture 
IMR-32 cells were obtained from American Type Culture Collection 
(Rockville, MD) (ATCC, CCL 127). IMR-32 cells were routinely cul- 
tured in 75 cm* culture flasks in minimum essential medium (MEM, 
Eagle) with Earle’s salts, non-essential amino acids and 10% fetal calf 
serum. Three days before the experiment, cells were seeded at 1.5. lo6 
cells/well in 35 mm culture dishes which had been pre-coated with 
human fibronectin at 5 &zm*. Cells were used between passages 53 
and 68. 
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2.3. Binding experiments 
Confluent cell monolayers were incubated for 1 h at 37°C with 1.2 
nM of [‘2sI]CCK-8-S (specific activity reduced to 267 Ci/mmol by unla- 
belled CCK-8-S) in physiological salt solution (PSS, composition: NaCl 
145 mM, KC1 5 mM, MgCl, 1 mM, CaCl, 1 mM, glucose 5.6 mM, 
bovine serum albumin 1 g/l, bacitracin 100 mg/l, HEPES-NaOH 5 mM, 
pH 7.4). The compounds to be tested were added simultaneously in 
solution in PSS. The reaction was stopped by three rapid washes with 
ice-cold PSS, cells were digested with NaOH 0.1 N and radioactivity 
in the resulting solution was determined in a gamma-counter. Non- 
snecific bindine was assessed bv addition of 1 uM of unlabelled CCK- 
s’-S. In the abience of cells, the specific binding of [‘*‘I]CCK-8-S to 
fibronectin-treated cell culture dishes was negligible. All experiments 
were carried out in duplicate. Experimental results were analysed by an 
in-house binding analysis program similar to LIGAND [16]. 
2.4. “Cd+ efjux experiments 
Confluent cell monolayers were incubated overnight with medium 
containing 5 ,&iiml of 45CaC1,. The experiment was started by removal 
of the medium and replacement by PSS devoid of 45Ca2+. The solution 
was removed every 30 s and replaced by fresh PSS. Radioactivity in the 
solution was determined by scintillation counting. Results were ex- 
pressed as fractional rate (R) of 45Ca efflux: 
R; = 
Qi 
Qc+& Qn 
where Q, = quantity of 45Cazc lost from the cells during time period i 
and Q, = quantity of “Ca” in the cells at the end of the experiment. 
4sCa2+ et&x was stimulated by addition of CCK-8-S to the washing 
solution after 8 medium changes. When the effect of antagonists were 
studied, they were present from the beginning of the experiment, i.e. for 
4 min before the addition of CCK-8-S. Inter-experiment variability of 
basal rates of 4’Ca2+ efIlux and of the maximal stimulation observed 
with CCK-8-S being quite high (80%), data were expressed as stimula- 
tion ratio’s (i.e. the ratio of the fractional rate of 45Ca2+ efilux during 
the stimulation interval divided by the rate of efflux during the interval 
immediately preceding stimulation. Under these conditions, variations 
were lower (20%). For inhibition studies, controls were always run in 
parallel, inhibition percentages under these conditions being highly 
reproducible (S.E.M. represented less than 5% of the mean). I& values 
and slope factors as well as the corresponding standard error were 
determined by fitting the logistic equation [17] to the pooled data from 
several experiments using the curve fitting package supplied with the 
SIGMAPLOT program (Jandel Scientific, Erkrath, Germany). 
3. Results and discwsion 
[1251]CCK-8-S binding was studied on IMR-32 cell monolay- 
ers at 37°C. Since non-specific binding represented 40-50% of 
total binding at 1 nM of ligand, experiments were performed 
by isotopic dilution of a fixed amount of [1251]CCK-8-S (1.2 
nM). As shown in Fig. lA, [‘*‘I]CCK-8-S bound to a single class 
of saturable, non-interacting binding sites, with a dissociation 
constant (Kn) of 4 ?I 1.5 nM and a maximum binding capacity 
(&A of 10,500 f 3,500 sites/cell (n = 6). These results were 
similar to those obtained in COS cells transfected with the rat 
pancreatic CCK, receptor, where [‘“IjCCK-8-S bound to a 
single class of binding sites with a dissociation constant of 1.5 
nM [ 111. Since at least two different classes of binding sites have 
been reported in other cell types like pancreatic acini, we took 
great care to detect other binding sites but we were unable to 
demonstrate the presence of low affiity binding sites on the 
surface of IMR-32 cells. However, as already observed in trans- 
fected COS cells, this may be due to the fact that only high 
affinity binding sites can be reliably detected in whole cells [ 111. 
The dissociation constant of [‘*‘I]CCK-8-S for its receptors was 
determined by association and dissociation kinetic experiments: 
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Fig. 1. l’ZSIjCCK-8-S binding to IMR-32 cells. (A) Equilibrium binding 
experiments. Cells were incubated for 1 h at 37°C with 1.2 nM of 
1’2511CCK-8-S and increasine concentrations of unlabelled CCK-8-S. 
bat’s shown are the mean OF two experiments and represent he total 
binding to the cells. The solid line represents the results of a non-linear 
regression analysis of the data to a one-site binding equation. 
(B) Association kinetics of [‘*‘I]CCK-8-S (1.2 nM) binding to IMR-32 
cells. (C) Dissociation kinetics. [‘251]CCK-8-S (1.2 nM) was incubated 
with cell monolayers for 1 h, then dissociation was induced by 1 PM 
of CCK-8-S. 
as shown in Fig. lB, association of [1251]CCK-8-S (1.2 nM) 
proceeded with a pseudo-first order kinetics, as evidenced by 
the linear plot. A mean k,,, value of 0.034 mine1 could thus be 
determined, corresponding to a half-time of association (tl12) of 
20 min. Dissociation of the [‘251]CCK-8-Slreceptor complex, 
initiated by the addition of an excess of unlabelled CCK-8-S 
(1 PM) proceeded in a mono-exponential manner (Fig. 1C) with 
a half-life of 29 min. From these results the dissociation rate 
constant value was found to be 4. 10e4 s-i. From the relation- 
ship kobs = k+, ([1251]CCK-8-S) +k_,, the association rate con- 
stant k,, was found to be 1.4.10’ M-‘.s-‘. Calculating the 
dissociation constant value (&) from these data gave Kd = k-J 
k,, = 2.8 nM, a value close to the Kd value determined previ- 
ously in the equilibrium binding experiments. 
The inhibition of [‘*‘I]CCK-8-S binding to IMR-32 cells by 
different compounds was then studied. As shown in Fig. 2A, 
binding of [1251]CCK-8-S was inhibited by unlabelled CCK-8-S 
with an IC,, value (concentration which inhibited 50% of the 
specific binding) of 4.2 nM. The non-sulphated analogue of 
CCK-8-S (CCK-8-NS), known to be active on the CCKB recep- 
tor [19], displaced [1zI]CCK-8-S from its binding sites on IMR- 
32 cells only when tested at high concentrations (Fig. 2B). 
[‘*-@ZCK-8-S (1 nM) binding to IMR-32 cells was inhibited by 
low concentrations of SR 27897, a specific non-peptide inhibi- 
tor of CCK-8-S binding to CCK, receptors [20] (It& = 1.5 
nM), whereas higher concentrations of the CCK, antagonist 
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PD 134,308 [4] were necessary to interfere with the binding of 
[‘251]CCK-8-S to these cells (ICsO = 0.36 PM). Although the 
inhibitory concentration of PD 134,308 was slightly lower than 
what could be expected from previous results under other ex- 
perimental conditions, the fact that non-sulphated CCK-8 was 
nearly inactive on [“‘I]CCK-8-S binding, and that PD 134,308 
was two orders of magnitude less active than the CCK,-selec- 
tive compound SR 27897, confirms that, on this cell type, 
[1251]CCK-8-S is binding to CCK, receptors. [i2’I’JCCK-8-S 
binding was inhibited by the CCK-8-S analogue CCK-JMV- 
180, which was active at concentrations very similar to those 
of CCK-8-S (IC,, = 1.7 nM). 
We then studied a functional response of CCKA receptor 
activation in IMR-32 cells: 45Ca2+ eftlux was studied because 
in rat pancreatic acini this response was induced by both CCK- 
8-S and CCK-JMV-180 [7,8]. As shown in Fig. 3, CCK-8-S (100 
nM) induced a rapid and transient increase in 45Ca2’ et&x from 
IMR-32 cells. 45Ca2+ efflux was maximal during the first 30 s 
of the presence of CCK-8-S and declined rapidly thereafter. 
This result was in close analogy to the transient increase in Ca2T 
observed after CCK-8-S stimulation of rat pancreatic acinar 
cells [7]. The 45Ca2’ efflux during the first 30 s of exposure was 
therefore routinely used to determine the effect of CCK-8-S and 
antagonists. CCK-8-NS did not induce any effect on 45Ca2’ 
efflux (2% increase in the presence of 1 PM CCK&NS). Since 
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Fig. 2. Effect of SR 27897 (A), CCK-JMV-180 (0), CCK-8-S (o), CCK- 
8-NS (0) and PD 134,308 (0) on [‘*‘I]CCK-8-S binding (1 nM) (A) and 
CCK-8-S (100 nM)-induced “Ca2+ et&ix (B). Results are expressed as 
percent of total binding or control response e5Caz+ efflux). Data are 
the mean of two determinations for binding experiments and of at least 
six determinations for 45Ca2’ efflux experiments. The solid lines repre- 
sent a fit of the logistic equation to the data. 
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Fig. 3. Effect of CCK-8-S on 45Caz’ efilux in IMR-32 cell monolayers. 
Medium was replaced every 30 s and 45Caz’ determined by scintillation 
counting. The horizontal bar denotes the presence of CCK-8-S (100 
nM) (m), CCK-JMV-180 (10pM) (0) or buffer (0). Data are the mean 
of three determinations on the same batch of cells. (Inset) Concentra- 
tion-effect relationship of the stimulatory effect of CCK-8-S. Data are 
given as stimulation ratio vs. the pre-stimulatory period and are the 
mean f S.E.M. of at least 5 determinations. 
CCK3-NS is as active as CCK-8-S on CCK, receptors [19], but 
less active on CCK, receptors, these data further suggest hat 
CCK-8-S acts through CCK, receptors to induce an increase 
in 45Ca2’ efflux in IMR-32 cells. 
Despite the fact that the 45Ca2+ et&x response was of a 
highly variable nature at low concentrations of CCK-8-S, a 
dose-effect relationship could be established (Fig. 3, inset). 
CCK-8-S increased 45Ca2c efllux with an EC5,, value of 4 nM. 
This concentration is higher than that which stimulates 45Ca2+ 
release in pancreatic acinar cells [7], but close to the K,, value 
obtained previously in the binding experiments and also similar 
to the concentration inducing an increase in phosphatidylino- 
sitol turnover, as has already been reported in CHP 212 neu- 
roblastoma cells [21]. This discrepancy between pancreatic aci- 
nar cells and neuroblastoma cells could be due to the lower 
receptor density in neuroblastoma cells [21]. CCK-JMV-180 
had no effect on 45Ca2’ efflux up to a concentration of 10 PM, 
that is, a concentration lOO-times higher than the concentration 
giving a maximal effect of CCK-8-S (Fig. 3). However, as 
shown in Fig. 2B, CCK-JMV-180 inhibited CCK-8-S (100 nM)- 
induced 45Ca2’ efllux at much lower concentrations. This effect 
occurred in a dose-dependent manner, with an IC,, value of 
50 nM. 
In order to confnm that the effects of CCK-8-S in these cells 
were mediated by CCK, receptors, the effects of SR 27897, 
a specific antagonist of CCK-8-S binding to the CCK, recep- 
tors, and PD 134308, specific for the CCK, receptors were 
determined. As shown in Fig. 2B, both compounds inhibited 
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CCK-8-S-stimulated 45Caz+ et&t, but a lOOO-fold difference 
was observed between both compounds, SR 27897 being active 
at very low concentrations (IC& = 32 nM). These data confirm 
that SR 27897, which has been shown to be a selective and high 
affinity antagonist of CCK, receptors in rat acini [19], is a 
potent antagonist of CCK-8-S on human CCK, receptors in 
neuroblastoma cells. 
From Fig. 2 it clearly appears that the rank order of potency 
of the antagonists is identical between [rz51]CCK-8-S binding 
and CCK-l-S-induced 45Ca2+ efflux. The concentrations neces- 
sary for inhibition of the Ca2’ response were about 304imes 
higher than those effective on [‘251]CCK-8-S binding but this 
may be due to the fact that near-maximal concentrations of 
CCK-8-S had to be used in order to obtain reliable responses 
with regard to 45Ca2+ efflux. 
The finding that CCK-JMV-180 acts as an antagonist of 
CCK-8-S-induced 45Ca2+ e&x in IMR-32 cells raises contro- 
versy with other results showing that, like CCK-8-S this com- 
pound acts as an agonist of the high affinity state of the CCK, 
receptor [6-lo]. However, it can not be excluded that a differ- 
ence between human and rat receptors may result in CCK- 
JMV-180 acting as an agonist on rat receptors and an antago- 
nist on human receptors. This is reminiscent of the fact that in 
mice, CCK-JMV-180 acts as a high affinity agonist of the sec- 
ond inhibitory phase of amylase release and of food intake, 
whereas it inhibits these responses in the rat [13]. However, the 
finding that CCK-JMV-180 inhibits CCK-8-S-induced 45Ca2’ 
efflux is also consistent with the idea that this compound acts 
as a partial agonist of the CCK, receptors, acting as an agonist 
in tissues were receptor-response coupling is strong and as an 
antagonist in other tissues [6]. This would explain why CCK- 
JMV-180 is able to activate phosphoinositide hydrolysis in 
CHO cells where CCK, receptors have been over-expressed, 
but not in rat pancreatic acini where the CCK, receptor density 
is lower [ll]. 
Whatever the mechanism distinguishing the effect of CCK- 
JMV-180 from that of CCK-8-S, this compound is a very inter- 
esting tool because it might be able to functionally discriminate 
CCK,-related responses in different tissues. However, our re- 
sults represent another example showing that caution must be 
taken in extrapolating results obtained in animal tissues to that 
in the human situation. 
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